UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
February 24, 2016
___________________________
Lombard Medical, Inc.
(Exact Name of Registrant as Specified in Its Charter)
N/A
(Translation of Registrant’s Name into English)
___________________________
Cayman Islands | 3841 | Not applicable |
(State or Other Jurisdiction of Incorporation or Organization) | (Primary Standard Industrial Classification Code Number) 6440 Oak Canyon Suite 200 Irvine, CA 92618 +866-790-1447 | (I.R.S. Employer Identification Number) |
(Address, Including ZIP Code, and Telephone Number, Including Area Code,
of Registrant’s Principal Executive Offices)
___________________________
Lombard Medical, Inc.
6440 Oak Canyon
Suite 200
Irvine, CA 92618
(Name, Address of Agent for Service)
___________________________
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-FX Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):o
On February 19, 2016, a Director of Lombard Medical, Inc. (the “Company”) purchased ordinary shares of the Company. The Company’s CEO Simon Hubbert purchased 600 shares in open market transactions at an average price of $0.85. Immediately following these transactions, Mr. Hubbert held 58,615 shares of the Company.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Lombard Medical, Inc. | |||
By: | /s/ William J. Kullback | ||
William J. Kullback | |||
Chief Financial Officer | |||
Date: February 24, 2016 |